UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $410
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $337 to $410.
March 15, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Eliana Merle reaffirms a Buy rating on Madrigal Pharmaceuticals and increases the price target to $410.
The upgrade in the price target by a reputable analyst like Eliana Merle from UBS is a strong positive signal for Madrigal Pharmaceuticals. It suggests confidence in the company's future performance and potential for growth, likely leading to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100